MET activation by its ligand HGF induces MET kinase catalytic activity, which triggers transphosphorylation of Tyr1234 and Tyr1235. These two tyrosines engage various signal transducers, thus initiating a whole spectrum of biological activities driven by MET, collectively known as the invasive growth program; proliferation and survival (resistance to apoptotic signals), increased cell motility, cell dissociation (scattering), epithelial tubulogenesis, infiltration of tissues, and stimulation of angiogenesis (Appleman et al). The transducers interact with the intracellular multisubstrate docking site of MET either directly, such as GRB2, SHC, SRC, and the p85 regulatory subunit of PI3K, or indirectly through the scaffolding protein GAB1. Phosphorylation of Tyr1349 and Tyr1356 of the multisubstrate docking site mediates interaction with GAB1, SRC, and SHC, while only Tyr 1356 is involved in the recruitment of GRB2, phospholipase C γ (PLC-γ), p85, and SHP2. GAB1 is a key coordinator of the cellular responses to MET and binds the MET intracellular region with high avidity, but low affinity. Upon interaction with MET, GAB1 becomes phosphorylated on several tyrosine residues which, in turn, recruit a number of signaling effectors, including PI3K, SHP2, and PLC-γ. GAB1 phosphorylation by MET results in a sustained signal that mediates most of the downstream signaling pathways. (Description adapted from [https://en.wikipedia.org/wiki/C-Met Wikipedia]). MET is a proto-oncogene, meaning that regulated expression of the wild-type allele plays a role in normal physiologic processes, and malignant transformation occurs when MET activity is increased in- appropriately and/or constitutively activated (Appleman et al). Phosphorylation sites were added based on information from PhosphoSitePlus (R), www.phosphosite.org. abd e43 cda c44 ad2 bbb f75 parentid=P08581; parentsymbol=MET; site=yVHVNAtyVNVKCVA; position=tyr1356; sitegrpid=448473; ptm=p; direction=u parentid=P08581; parentsymbol=MET; site=RDMyDkEyysVHNkt; position=tyr1234; sitegrpid=448470; ptm=p; direction=u parentid=P08581; parentsymbol=MET; site=DMyDkEyysVHNktG; position=tyr1235; sitegrpid=448471; ptm=p; direction=u parentid=P08581; parentsymbol=MET; site=stFIGEHyVHVNAty; position=tyr1349; sitegrpid=448472; ptm=p; direction=u parentid=P04049; parentsymbol=RAF1; site=IGDFGLAtVksRWsG; position=thr491; sitegrpid=447748; ptm=p; direction=u parentid=Q02750; parentsymbol=MAP2K1; site=VsGQLIDsMANsFVG; position=ser218; sitegrpid=448514; ptm=p; direction=u parentid=Q02750; parentsymbol=MAP2K1; site=LIDsMANsFVGTRSY; position=ser222; sitegrpid=448513; ptm=p; direction=u parentid=P36507; parentsymbol=MAP2K2; site=VsGQLIDsMANsFVG; position=ser222; sitegrpid=448073; ptm=p; direction=u parentid=P36507; parentsymbol=MAP2K2; site=LIDsMANsFVGTRSY; position=ser226; sitegrpid=448074; ptm=p; direction=u parentid=P28482; parentsymbol=MAPK1; site=HtGFLtEyVAtRWyR; position=tyr187; sitegrpid=447594; ptm=p; direction=u parentid=P28482; parentsymbol=MAPK1; site=HDHtGFLtEyVAtRW; position=thr185; sitegrpid=447593; ptm=p; direction=u parentid=P27361; parentsymbol=MAPK3; site=HtGFLtEyVAtRWyR; position=tyr204; sitegrpid=447543; ptm=p; direction=u parentid=P27361; parentsymbol=MAPK3; site=HDHtGFLtEyVAtRW; position=thr202; sitegrpid=447542; ptm=p; direction=u parentid=Q92934; parentsymbol=BAD; site=PFrGrsRsAPPNLWA; position=ser99; sitegrpid=447862; ptm=p; direction=d parentid=P14921; parentsymbol=ETS1; site=CADVPLLtPSSkEMM; position=thr38; sitegrpid=447950; ptm=p; direction=d parentid=P05412; parentsymbol=JUN; site=kNsDLLtsPDVGLLk; position=ser63; sitegrpid=447686; ptm=p; direction=d parentid=P05412; parentsymbol=JUN; site=VGLLkLAsPELERLI; position=ser73; sitegrpid=447943; ptm=p; direction=d abd abd abd e43 abd abd a87 cancer pathway PW:0000605 Pathway Ontology endothelial cell CL:0000115 Cell Type 24812413 PubMed MET as a target in papillary renal cell carcinoma. Clin Cancer Res 2014 Fay AP Signoretti S Choueiri TK epithelial cell CL:0000066 Cell Type 25514926 PubMed PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res 2015 Hornbeck PV Zhang B Murray B Kornhauser JM Latham V Skrzypek E 26536169 PubMed Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2016 Linehan WM Spellman PT Ricketts CJ Creighton CJ Fei SS Davis C Wheeler DA Murray BA Schmidt L Vocke CD Peto M Al Mamun AA Shinbrot E Sethi A Brooks S Rathmell WK Brooks AN Hoadley KA Robertson AG Brooks D Bowlby R Sadeghi S Shen H Weisenberger DJ Bootwalla M Baylin SB Laird PW Cherniack AD Saksena G Haake S Li J Liang H Lu Y Mills GB Akbani R Leiserson MD Raphael BJ Anur P Bottaro D Albiges L Barnabas N Choueiri TK Czerniak B Godwin AK Hakimi AA Ho TH Hsieh J Ittmann M Kim WY Krishnan B Merino MJ Mills Shaw KR Reuter VE Reznik E Shelley CS Shuch B Signoretti S Srinivasan R Tamboli P Thomas G Tickoo S Burnett K Crain D Gardner J Lau K Mallery D Morris S Paulauskis JD Penny RJ Shelton C Shelton WT Sherman M Thompson E Yena P Avedon MT Bowen J Gastier-Foster JM Gerken M Leraas KM Lichtenberg TM Ramirez NC Santos T Wise L Zmuda E Demchok JA Felau I Hutter CM Sheth M Sofia HJ Tarnuzzer R Wang Z Yang L Zenklusen JC Zhang J Ayala B Baboud J Chudamani S Liu J Lolla L Naresh R Pihl T Sun Q Wan Y Wu Y Ally A Balasundaram M Balu S Beroukhim R Bodenheimer T Buhay C Butterfield YS Carlsen R Carter SL Chao H Chuah E Clarke A Covington KR Dahdouli M Dewal N Dhalla N Doddapaneni HV Drummond JA Gabriel SB Gibbs RA Guin R Hale W Hawes A Hayes DN Holt RA Hoyle AP Jefferys SR Jones SJ Jones CD Kalra D Kovar C Lewis L Ma Y Marra MA Mayo M Meng S Meyerson M Mieczkowski PA Moore RA Morton D Mose LE Mungall AJ Muzny D Parker JS Perou CM Roach J Schein JE Schumacher SE Shi Y Simons JV Sipahimalani P Skelly T Soloway MG Sougnez C Tam A Tan D Thiessen N Veluvolu U Wang M Wilkerson MD Wong T Wu J Xi L Zhou J Bedford J Chen F Fu Y Gerstein M Haussler D Kasaian K Lai P Ling S Radenbaugh A Van Den Berg D Weinstein JN Zhu J Albert M Alexopoulou I Andersen JJ Auman JT Bartlett J Bastacky S Bergsten J Blute ML Boice L Bollag RJ Boyd J Castle E Chen YB Cheville JC Curley E Davies B DeVolk A Dhir R Dike L Eckman J Engel J Harr J Hrebinko R Huang M Huelsenbeck-Dill L Iacocca M Jacobs B Lobis M Maranchie JK McMeekin S Myers J Nelson J Parfitt J Parwani A Petrelli N Rabeno B Roy S Salner AL Slaton J Stanton M Thompson RH Thorne L Tucker K Weinberger PM Winemiller C Zach LA Zuna R 11114738 PubMed Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000 Furge KA Zhang YW Vande Woude GF 22128289 PubMed An overview of the c-MET signaling pathway. Ther Adv Med Oncol 2011 Organ SL Tsao MS papillary renal cell carcinoma DOID:4465 Disease disease pathway PW:0000013 Pathway Ontology 22042966 PubMed MET signaling pathway: a rational target for cancer therapy. J Clin Oncol 2011 Appleman LJ 19496715 PubMed Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009 Giubellino A Linehan WM Bottaro DP cancer DOID:162 Disease 20303741 PubMed Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010 Cecchi F Rabe DC Bottaro DP